Skip to content

Mixed Phenotype Acute Leukemia B Myeloid C3472616

Published: July 22, 2026Updated: August 20, 2026

A rare blood cancer with features of both lymphoid and myeloid leukemia cells, affecting children and adults. Treatment involves intensive chemotherapy and often stem cell transplant, with serious prognosis.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
C96.9
ICD-11
2A00.0
Body system
hematologic
Severity
critical
Chronic
false

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Generalized symptoms

Symptoms may be severe and require urgent medical attention.

Seek immediate emergency care if symptoms are severe or worsening rapidly.

!

Severe headache

Fatigue

(hematologic)

Mucosal bleeding

(hematologic)

Bone pain

(hematologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Acute myeloid leukemia-style induction

Intensive '7+3' cytarabine-based chemotherapy with anthracycline addition targeting the myeloid component of biphenotypic leukemia. May include anti-CD33 antibodies.

medication
2

Standard interventional procedure protocol

Requires immediate emergency medical intervention. Do not delay treatment.

procedure
3

Lymphoid-directed therapy components

Incorporation of vincristine, corticosteroids, and sometimes methotrexate to address the lymphoid component of B-myeloid mixed phenotype acute leukemia.

medication

Additional treatment options

Consolidation with transplant evaluation

Post-remission therapy including high-dose chemotherapy with autologous or allogeneic stem cell transplant consideration based on risk stratification and donor availability.

procedure

Immunotherapy consideration

Blinatumomab or other bispecific antibody therapy may be considered for residual lymphoid component or during relapse, targeting CD19 on B-cell populations.

medication

Response-adapted monitoring

Flow cytometry and molecular monitoring to assess lineage composition and detect minimal residual disease. Imaging for extramedullary involvement.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

Call emergency services (911) immediately

!

Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.

Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.

Frequently asked questions

Common questions about this topic.

Q

What is Mixed Phenotype Acute Leukemia B Myeloid C3472616?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Weinberg OK, Arber DA, Pai RK. Diagnosis and management of mixed phenotype acute leukemia guidelines. Haematologica. 2022.

guideline2022
2

Matutes E, Morilla R, Meeus P. Mixed phenotype acute leukemia: clinical features and outcomes. Blood Rev. 2021.

review2021
3

Liu H, Chen Y, Wang J, Zhang X. Intensive chemotherapy followed by transplantation in mixed phenotype acute leukemia: a prospective study. J Clin Oncol. 2020.

clinical_trial2020
4

Bachir AA, Alsharif F, Hassan R. Immunophenotypic and molecular characterization of B-myeloid mixed phenotype acute leukemia. Leukemia. 2023.

review2023

Medication Comparisons

Compare medications used to treat Mixed Phenotype Acute Leukemia B Myeloid C3472616. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy